

## PHARMACY POLICY STATEMENT

### North Carolina Marketplace

<b>DRUG NAME</b>	<b>Voxzogo (vosoritide)</b>
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Voxzogo, initially approved by the FDA in 2021, is a C type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. It acts as a positive

